Dec 07, 2023
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Nov 22, 2023
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Nov 09, 2023
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Nov 06, 2023
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Nov 02, 2023
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Nov 01, 2023
Immutep to Participate in November Investor Events
Oct 30, 2023
Immutep Quarterly Activities Report Q1 FY24
Oct 25, 2023
Immutep Receives ~A$1.13 Million R&D Tax Incentive
Oct 24, 2023
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Oct 22, 2023
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Oct 15, 2023
Immutep Announces Publication of Abstracts at ESMO Congress 2023
Oct 02, 2023
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
